Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday

Broadcom's disappointing AI-chip guidance triggered a semiconductor sell-off, dragging down the Nasdaq while the S&P 500 and Dow Jones gained on sector rotation and value tailwinds. Healthcare stocks rallied with Eli Lilly and NovoCure posting strong gains. The pullback raises questions about AI stock valuations and whether the semiconductor sector's 170% annual rally is cooling.

06/04/2026, 12:39 PM • The Motley Fool

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

05/27/2026, 1:00 PM • GlobeNewswire

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.

02/17/2026, 11:17 AM • Benzinga

Soleus Adds a Significant Number of Celcuity Shares

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.

02/13/2026, 7:34 AM • The Motley Fool

FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer

The FDA has approved Optune Pax, a portable non-invasive device developed by Novocure that delivers tumor treating fields (TTFields) to treat locally advanced pancreatic cancer. The device, which received Breakthrough Device designation, showed approximately two months improvement in overall survival when combined with standard chemotherapy in clinical trials.

02/12/2026, 12:57 PM • GlobeNewswire

Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED)

U.S. stock futures rose on Thursday following a strong January jobs report showing 130,000 jobs added, exceeding expectations. The report dampened rate cut expectations, with markets pricing in only a 6% chance of a March rate cut. Key movers include Micron (up 3.3%), Novocure (up 33% on FDA approval), and Fastly (up 43% on strong earnings), while AppLovin fell 4.95% despite beating expectations.

02/12/2026, 8:31 AM • Benzinga

Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report—Micron, Novocure, Fastly In Focus

U.S. stock futures rose on Thursday following a strong January jobs report showing 130,000 jobs added, exceeding expectations. The report reduced expectations for Federal Reserve rate cuts, with markets pricing in only a 6% chance of a March cut. Key movers include Micron (up 3.3%), Novocure (up 33% on FDA approval), and Fastly (up 43% on strong earnings), while AppLovin fell 4.95% despite beating expectations.

02/12/2026, 6:19 AM • Benzinga

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure announced positive results from its Phase 3 METIS trial, demonstrating that Tumor Treating Fields (TTFields) therapy can significantly delay brain metastasis progression in non-small cell lung cancer patients without causing neurocognitive side effects.

09/29/2025, 4:30 PM • Benzinga

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

Wall Street analysts are bullish on Viking Therapeutics and NovoCure, two healthcare stocks with significant potential growth despite recent market challenges in their clinical trials and product launches.

08/29/2025, 4:26 AM • The Motley Fool

Novocure: Steady Ahead of Key Milestones

Novocure reported 6% revenue growth and 9% patient growth, with plans to seek FDA approval for pancreatic and brain cancer treatments. Despite not being profitable, the company maintains significant cash reserves and potential for future development.

07/24/2025, 9:21 AM • The Motley Fool